Pharmaceutical Technology on MSN7d
Biosimilars drive Sandoz growth ahead of unclear tariff effects in 2025Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...
The commercial availability of Pyzchiva®, which builds on the US launch of Hyrimoz® in July 2023, marks an important step in the Sandoz strategic ambition to become number one in biosimilars in ...
Sandoz recently launched Hyrimoz, a biosimilar for Humira, and has over 20 biosimilar assets in pipeline including biosimilars for Tysabri, Prolia/Xgeva, Stelara, and Eylea. In Europe and other ...
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesMEDIA RELEASEFY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in ...
Sandoz pointed to the uptake of its Humira biosimilar Hyrimoz in the US through a private-label agreement with CVS biosimilar subsidiary Cordavis as one of the drivers of its biosimilar business ...
In April, Sandoz leveraged a private-label agreement in the US to accelerate patient switching to its biosimilar; Hyrimoz® (adalimumab) is now the leading adalimumab biosimilar in the US market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback